Trial results

Effects of Insulin Glargine and Lixisenatide on the Brain

NCT03881995 on ClinicalTrials.gov · last registry update 2020-07-10

Stopped early, having planned 1 participants. The sponsor logged completion for 29 June 2020. Primary outcome, as filed: Brain insulin sensitivity. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

TERMINATED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

University Hospital Tuebingen

Sponsor type

Other

Enrollment

1

Started

2019-03-18

Primary completion

2020-06-29 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Brain insulin sensitivity

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.